Trace Contamination of Over-the-Counter Androstenedione and Positive Urine Test Results for a Nandrolone Metabolite
CONTEXT Several anabolic steroids are sold over-the-counter (OTC) in the United States, and their production is not regulated by the US Food and Drug Administration. Reports have suggested that use of these supplements can cause positive urine test results for metabolites of the prohibited steroid n...
Gespeichert in:
Veröffentlicht in: | JAMA : the journal of the American Medical Association 2000-11, Vol.284 (20), p.2618-2621 |
---|---|
Hauptverfasser: | , , , , , , |
Format: | Artikel |
Sprache: | eng |
Schlagworte: | |
Online-Zugang: | Volltext |
Tags: |
Tag hinzufügen
Keine Tags, Fügen Sie den ersten Tag hinzu!
|
Zusammenfassung: | CONTEXT Several anabolic steroids are sold over-the-counter (OTC) in the United
States, and their production is not regulated by the US Food and Drug Administration.
Reports have suggested that use of these supplements can cause positive urine
test results for metabolites of the prohibited steroid nandrolone. OBJECTIVES To assess the content and purity of OTC androstenedione and to determine
if androstenedione and 19-norandrostenedione administration causes positive
urine test results for 19-norandrosterone, a nandrolone metabolite. DESIGN Randomized controlled trial of androstenedione, open-label trial of
19-norandrostenedione, and mass spectrometry of androstenedione preparations,
conducted between October 1998 and April 2000. SETTING Outpatient facility of a university hospital. PARTICIPANTS A total of 41 healthy men aged 20 to 44 years. INTERVENTION Participants were randomly assigned to receive oral androstenedione,
100 mg/d (n = 13) or 300 mg/d (n = 11) for 7 days, or no androstenedione (n
= 13); in addition, 4 patients received 10 µg of 19-norandrostenedione. MAIN OUTCOME MEASURES Content of OTC androstenedione preparations; level of 19-norandrosterone
in urine samples, determined by mass spectrometry, compared among the 3 randomized
groups at day 1 and day 7, and among the participants who received 19-norandrostenedione
from October 1998 to April 2000. RESULTS All urine samples from participants treated with androstenedione contained
19-norandrosterone, while no samples from the no-androstenedione group did.
Urinary concentrations were averaged for day 1 vs day 7 measurements; mean
(SD) 19-norandrosterone concentrations in the 100-mg/d and 300-mg/d groups
were 3.8 (2.5) ng/mL and 10.2 (6.9) ng/mL, respectively (P = .006). The 19-norandrosterone content exceeded the cutoff for reporting
positive cases (>2.0 ng/mL) in 20 of 24. The androstenedione preparation used
was pure at a sensitivity of 0.1%, but at 0.001% 19-norandrostenedione was
found. For the 4 participants to whom 10 µg of 19-norandrostenedione
was administered, 19-norandrosterone was found in all urine samples. Of 7
brands of androstenedione analyzed at the 1% level, 1 contained no androstenedione,
1 contained 10 mg of testosterone, and 4 more contained 90% or less of the
amount stated on the label. CONCLUSION Our study suggests that trace contamination of androstenedione with
19-norandrostenedione is sufficient to cause urine test results positive for
19-norandrosterone, the standard mar |
---|---|
ISSN: | 0098-7484 1538-3598 |
DOI: | 10.1001/jama.284.20.2618 |